MARKET

ALNY

ALNY

Alnylam Pharmaceuticals Inc
NASDAQ
224.60
-4.05
-1.77%
After Hours: 228.99 +4.39 +1.95% 18:34 08/17 EDT
OPEN
225.76
PREV CLOSE
228.65
HIGH
227.99
LOW
222.12
VOLUME
1.54M
TURNOVER
--
52 WEEK HIGH
495.55
52 WEEK LOW
197.81
MARKET CAP
30.05B
P/E (TTM)
38.23
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ALNY last week (0810-0814)?
Weekly Report · 19h ago
Alnylam price target lowered to $256 from $316 at Wells Fargo
TipRanks · 1d ago
Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing
The Motley Fool · 1d ago
NASDAQ: ALNY Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm
Barchart · 3d ago
Alnylam Pharmaceuticals Is Maintained at Equal-Weight by Wells Fargo
Dow Jones · 3d ago
Alnylam Pharmaceuticals Price Target Cut to $256.00/Share From $316.00 by Wells Fargo
Dow Jones · 3d ago
Wells Fargo Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $256
Benzinga · 3d ago
Alnylam Pharma (ALNY) Gets a Hold from Wells Fargo
TipRanks · 3d ago
More
About ALNY
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in adults ; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Zilebesiran, Elebsiran, Mivelsiran, ALN-6400, and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.

Webull offers Alnylam Pharmaceuticals, Inc. stock information, including NASDAQ: ALNY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALNY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALNY stock methods without spending real money on the virtual paper trading platform.